[Clinical evaluation of new anti-arrhythmia drugs after the CAST (Cardiac Arrhythmia Suppression Trial) study].
The results of the Cardiac Arrhythmia Suppression Trial (CAST) are of great importance for the development and clinical evaluation of new antiarrhythmic agents. Today, the development of a new antiarrhythmic drug is only justified, if the benefit risk ratio is superior compared to those agents already available in clinical practice. The primary criterion of therapeutic efficacy is the prevention of tachyarrhythmic sudden cardiac death and/or the prevention of sustained ventricular tachycardia.
Meinertz
T
T
II. Medizinische Abteilung, Allgemeines Krankenhaus St. Georg, Hamburg.
Zehender
M
M
Hohnloser
S H
SH
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic / Q000379:methods*; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D004562:Electrocardiography / Q000187:drug effects; D006801:Humans; D015996:Survival Rate; D013610:Tachycardia / Q000139:chemically induced / Q000188:drug therapy / Q000401:mortality
D000889:Anti-Arrhythmia Agents
Klinische Bewertung neuer Antiarrhythmika nach der CAST-Studie.